Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Subscribe To Our Newsletter & Stay Updated
